• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Rallybio Corporation

    2/17/26 4:26:58 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLYB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Rallybio Corporation

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    75120L100

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    75120L100


    1Names of Reporting Persons

    VIKING GLOBAL INVESTORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,222,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,222,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,222,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    75120L100


    1Names of Reporting Persons

    Viking Global Opportunities Parent GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,222,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,222,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,222,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    75120L100


    1Names of Reporting Persons

    Viking Global Opportunities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,222,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,222,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,222,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    75120L100


    1Names of Reporting Persons

    Viking Global Opportunities Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,222,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,222,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,222,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    75120L100


    1Names of Reporting Persons

    Viking Global Opportunities Illiquid Investments Sub-Master LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,222,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,222,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,222,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    75120L100


    1Names of Reporting Persons

    HALVORSEN OLE ANDREAS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NORWAY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,222,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,222,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,222,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    75120L100


    1Names of Reporting Persons

    Ott David C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,222,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,222,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,222,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    75120L100


    1Names of Reporting Persons

    Shabet Rose Sharon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,222,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,222,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,222,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Rallybio Corporation
    (b)Address of issuer's principal executive offices:

    234 Church Street, Suite 1020, New Haven, Connecticut, 06510
    Item 2. 
    (a)Name of person filing:

    Viking Global Investors LP ("VGI"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"), O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
    (c)Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP and Opportunities Portfolio GP are Delaware limited liability companies; VGOP is a Cayman Islands exempted limited partnership; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    75120L100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    This Statement on Schedule 13G relates to shares of Common Stock and pre-funded warrants to purchase shares of Common Stock with an exercise price of $0.0001 per share (the "Warrants") held directly by VGOP. VGOP directly owns 4,194,777 shares of Common Stock and Warrants with the right to purchase 3,333,388 shares of Common Stock. However, the terms of the Warrants provide that no holder of Warrants shall have the right to exercise any portion of the Warrants to the extent that, after giving effect to such issuance after exercise, such holder of Warrants (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately following exercise (the "Blocker"). Any holder of Warrants, upon notice to the Issuer, may increase or decrease the Blocker, subject to a maximum of 19.99%, but any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Issuer. Accordingly, the amount of shares of Common Stock reported as beneficially owned by the Reporting Persons set forth herein excludes shares of Common Stock that the Reporting Persons do not currently have the right to purchase upon exercise of the Warrants held directly by VGOP due to the Blocker. VGI: 4,222,969 VGI provides managerial services to VGOP. VGI has the authority to dispose of and vote the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. VGI does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Act"), VGI may be deemed to beneficially own the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. VGI beneficially owns 4,222,969 shares of Common Stock consisting of 4,194,777 shares of Common Stock directly owned by VGOP and 28,192 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to purchase upon exercise of the Warrants, subject to the Blocker. Opportunities Parent: 4,222,969 Opportunities Parent is the sole member of Opportunities GP, which has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Opportunities Parent does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 of the Act, Opportunities Parent may be deemed to beneficially own the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Opportunities GP: 4,222,969 Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Opportunities GP does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 of the Act, Opportunities GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Opportunities Portfolio GP: 4,222,969 Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Opportunities Portfolio GP does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 of the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. VGOP: 4,222,969 VGOP has the authority to dispose of and vote the shares of Common Stock that it directly owns or has the right to purchase upon exercise of the Warrants directly owned by it, subject to the Blocker, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 4,222,969 Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any shares of Common Stock or Warrants. Based on Rule 13d-3 of the Act, each may be deemed to beneficially own the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Mr. Halvorsen, Mr. Ott and Ms. Shabet each beneficially own 4,222,969 shares of Common Stock consisting of 4,194,777 shares of Common Stock directly owned by VGOP and 28,192 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to purchase upon exercise of the Warrants, subject to the Blocker.
    (b)Percent of class:

    The percentages set forth herein are based on (i) 42,243,774 shares of Common Stock outstanding as of December 30, 2025, as reported by the Issuer in its proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the "Commission") on January 2, 2026, and (ii) 28,192 shares of Common Stock that the Reporting Persons currently have the right to purchase upon exercise of the Warrants, subject to the Blocker. VGI: 9.99% Opportunities Parent: 9.99% Opportunities GP: 9.99% Opportunities Portfolio GP: 9.99% VGOP: 9.99% O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (ii) Shared power to vote or to direct the vote:

    VGI: 4,222,969 Opportunities Parent: 4,222,969 Opportunities GP: 4,222,969 Opportunities Portfolio GP: 4,222,969 VGOP: 4,222,969 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 4,222,969

     (iii) Sole power to dispose or to direct the disposition of:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (iv) Shared power to dispose or to direct the disposition of:

    VGI: 4,222,969 Opportunities Parent: 4,222,969 Opportunities GP: 4,222,969 Opportunities Portfolio GP: 4,222,969 VGOP: 4,222,969 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 4,222,969

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The response to Item 4 is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    VIKING GLOBAL INVESTORS LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities Parent GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
    Date:02/17/2026
     
    HALVORSEN OLE ANDREAS
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
    Date:02/17/2026
     
    Ott David C.
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
    Date:02/17/2026
     
    Shabet Rose Sharon
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
    Date:02/17/2026

    Comments accompanying signature:  (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).
    Exhibit Information

    EXHIBIT A - JOINT FILING AGREEMENT

    Get the next $RLYB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLYB

    DatePrice TargetRatingAnalyst
    4/9/2025Buy → Neutral
    H.C. Wainwright
    5/15/2024Overweight → Neutral
    JP Morgan
    2/7/2024$7.00 → $1.50Buy → Hold
    Jefferies
    4/17/2023$18.00Buy
    H.C. Wainwright
    4/10/2023$17.00Outperform
    Wedbush
    12/9/2022$21.00Overweight
    JP Morgan
    2/22/2022$32.00Mkt Outperform
    JMP Securities
    8/23/2021$40.00Outperform
    Evercore ISI Group
    More analyst ratings

    $RLYB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

    – Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion Refractoriness Currently Planned for 2H 2026 with Potential for Topline Data in 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial evaluating RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor

    2/17/26 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Announces Reverse Stock Split of Common Stock

    Rallybio Corporation (NASDAQ:RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio's Amended and Restated Certificate of Incorporation (the "Amendment") to effect the reverse stock split at a Special Meeting of Stockholders held on January 26, 2026. The reverse stock split is intended to give Rallybio greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Rallybio common stock to enable Rallybio to satisfy the minimum price requirement for continued listing on the Nasdaq Capital Market. Pursuant to the Amendmen

    2/3/26 4:05:00 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

    – RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash Runway Extended through 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent company developments. "In the third quarter, we continued to execute with discipline and focus, advancing our lead program, RLYB116, and achieving a key clinical milestone with the completion of dosing in Cohort 1 in our confirmatory PK/PD P

    11/6/25 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Rallybio Corporation

    SCHEDULE 13G/A - Rallybio Corp (0001739410) (Subject)

    2/17/26 4:26:58 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Rallybio Corp (0001739410) (Filer)

    1/29/26 5:14:47 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Rallybio Corporation

    DEF 14A - Rallybio Corp (0001739410) (Filer)

    1/2/26 4:05:33 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Boudreau Helen M

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:10:09 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chung Wendy

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:09:20 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hunt Ronald

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:08:25 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rallybio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Rallybio from Buy to Neutral

    4/9/25 8:36:28 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio downgraded by JP Morgan

    JP Morgan downgraded Rallybio from Overweight to Neutral

    5/15/24 7:39:44 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio downgraded by Jefferies with a new price target

    Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously

    2/7/24 6:42:56 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Financials

    Live finance-specific insights

    View All

    Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

    Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

    7/8/25 8:00:00 AM ET
    $RLYB
    $RXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

    -- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea

    12/20/23 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

    SC 13G/A - Rallybio Corp (0001739410) (Subject)

    11/12/24 10:34:15 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rallybio Corporation

    SC 13G - Rallybio Corp (0001739410) (Subject)

    7/30/24 9:06:36 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

    SC 13G/A - Rallybio Corp (0001739410) (Subject)

    7/30/24 12:47:55 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Leadership Updates

    Live Leadership Updates

    View All

    Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

    -- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart

    6/29/23 7:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

    -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results

    3/6/23 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban

    1/31/23 4:05:00 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care